SAMHSA – FAQs for Opioid Use Disorder Prescribing and Dispensing in the COVID-19 Emergency

In response to the Novel Coronavirus Disease (COVID-19) pandemic, SAMHSA is providing answers to Frequently Asked Questions regarding the provision of methadone and buprenorphine for the treatment of Opioid Use Disorder for new and existing patients.

FAQ’s Link

This post expires and will no longer be available at 11:11 am on Saturday, March 20th, 2021

Tags:
0 Comments

Leave a reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

National Association of Drug Diversion Investigators Federal Tax ID: 52-1660752 / DUNS Number: 073539913

Copyright © 2020 - NADDI. All Rights Reserved. Privacy Policy / Trademark Policy / Copyright Policy / Refund Policy

Log in with your credentials

or    

Forgot your details?

Create Account